ORIGINAL RESEARCH
Accepted on 14 May 2025
Insights into Immune-Related Adverse Events in Colorectal Cancer Patients Receiving Neoadjuvant Immunotherapy: Findings from a Multicenter Registry Study
doi 10.3389/fimmu.2025.1529637
- 164 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Cancer Therapy Related Organ Toxicities
Cancer Therapy Related Organ Toxicities
2,511
Total downloads
11k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 28 Apr 2025
Moderate toxicity with late onset as a good omen: association between toxicity and survival in the checkpoint inhibitor immunotherapy—a single center experience
doi 10.3389/fimmu.2025.1527103
- 755 views
CASE REPORT
Published on 04 Apr 2025
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy
doi 10.3389/fimmu.2025.1563736
- 2,724 views
- 1 citation
CASE REPORT
Published on 01 Apr 2025
Immune checkpoint inhibitor-induced anti-Hu antibody-associated gastrointestinal pseudo-obstruction: a case report and literature review
doi 10.3389/fimmu.2025.1555790
- 1,115 views
- 2 citations
ORIGINAL RESEARCH
Published on 12 Mar 2025
Resveratrol alleviates testicular toxicity induced by anti-PD-1 through regulating the NRF2-SLC7A11-GPX4 pathway
doi 10.3389/fimmu.2025.1529991
- 1,773 views
ORIGINAL RESEARCH
Published on 20 Feb 2025
Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide
doi 10.3389/fimmu.2025.1530919
- 646 views
ORIGINAL RESEARCH
Published on 24 Dec 2024
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
doi 10.3389/fimmu.2024.1503316
- 1,313 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: